BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 19, 2006
View Archived Issues
CTI, Novartis Enter Xyotax Deal; Option On Pixantrone
In a two-part arrangement, Cell Therapeutics Inc. agreed to partner Xyotax (poliglumex paclitaxel) with Novartis AG in a deal worth up to $285 million, and there's an option for another $111.5 million deal for pixantrone. (BioWorld Today)
Read More
TransTech RAGE Modulators Subject Of $173M Pfizer Deal
Read More
Glaxo Submits Application For Tykerb In Breast Cancer
Read More
Syntonix Gets Serono Vote Again: Potential $54M Deal
Read More
Sirion Gains $25M Through Takeover By Tenby Pharma
Read More
Appointments And Advancements
Read More
Clinic Roundup
Read More
Other News To Note
Read More